← All trials
NCT01138735
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2010
- Primary completion
- Aug 1, 2011
- Completion date
- Aug 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 285
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GaldermaLead sponsor
- Dermatology Specialists ResearchOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- University of CincinnatiOverall official - principal investigator
- Guildford Dermatology SpecialistsOverall official - principal investigator
- Zoe Draelos, MDOverall official - principal investigator
- FXM Research MiramarOverall official - principal investigator
- Adult & Pediatric DermatologyOverall official - principal investigator
- Nexus Clinical ResearchOverall official - principal investigator
- Dermatology Associates of Kingsport, PCOverall official - principal investigator
- North Bay Dermatology CentreOverall official - principal investigator
- Palmetto Clinical Trial Services, LLCOverall official - principal investigator
- Somerset Skin CentreOverall official - principal investigator
- Minnesota Clinical Study CenterOverall official - principal investigator
- Lynderm Research IncOverall official - principal investigator
- Premier Research GroupOverall official - principal investigator
- Redwood Dermatology CenterOverall official - principal investigator
- Henry Ford Health SystemOverall official - principal investigator
- Wake Forest UniversityOverall official - principal investigator
- UltraNova SkincareOverall official - principal investigator
- GaldermaStudy director
- Pennsylvania State UniversityOverall official - principal investigator
- University of Alabama, BirminghamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.